Advertisement

Quelle place pour les stratégies médicales adjuvante et néoadjuvante en phase localisée?

  • Jean-Jacques Patard
  • Alain Ravaud
  • Stéphane Oudard
Chapter
  • 334 Downloads
Part of the Oncologie pratique book series (ONCOLPRAT)

Abstrait

Dans une vue très schématique, il existe trois grands groupes de cancers du rein en termes de risque pronostique. Un premier groupe est celui qui a une très grande probabilité ďêtre guéri par la chirurgie seule. Il est communément admis que les tumeurs qui correspondent à ce groupe sont des tumeurs confinées au rein (<pT2), de bas grade, incidentales. Un deuxième groupe comprend des patients avec des tumeurs qui ont un risque significatif de ne pas être guéries de manière durable par la chirurgie, même si ľexérèse est macroscopique, complète, et même s’il n'existe pas de métastases au moment du diagnostic. Il s’agira volontiers dans ce cas de tumeurs symptomatiques, de grande taille, de haut grade ou localement avancées. Le troisième groupe est celui qui n'a aucune chance ďêtre guéri par la chirurgie seule et c'est typiquement le groupe des patients métastatiques pour lequel un traitement systémique est requis avec ou sans néphrectomie.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. 1.
    Kim HL, Seligson D, Liu X et al. (2004) Using protein expressions to predict survival in clear cell renal carcinoma. Clin Cancer Res 10: 5464–71PubMedCrossRefGoogle Scholar
  2. 2.
    Zisman A, Pantuck AJ, Wieder J et al. (2002) Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol 20: 4559–66PubMedCrossRefGoogle Scholar
  3. 3.
    Patard JJ, Kim HL, Lam JS et al. (2004) Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study. J Clin Oncol 22: 3316–22PubMedCrossRefGoogle Scholar
  4. 4.
    Frank I, Blute ML, Cheville JC et al. (2002) An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol 168: 2395–400PubMedCrossRefGoogle Scholar
  5. 5.
    Ficarra V, Martignoni G, Lohse C et al. (2006) External validation of the Mayo Clinic Stage, Size, Grade and Necrosis (SSIGN) Score to predict cancer specific survival using a european series of conventional renal cell carcinoma. J Urol 175: 1235–9PubMedCrossRefGoogle Scholar
  6. 6.
    Zisman A, Pantuck AJ, Dorey F et al. (2001) Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol 19: 1649–57PubMedGoogle Scholar
  7. 7.
    Messing EM, Manola J, Wilding G et al. (2003) Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. J Clin Oncol 21: 1214–22PubMedCrossRefGoogle Scholar
  8. 8.
    Pizzocaro G, Piva L, Colavita M et al. (2001) Interferon adjuvant to radical nephrectomy in Robson stages II and III renal carcinoma: a multicentric randomized study. J Clin Oncol 19: 425–31PubMedGoogle Scholar
  9. 9.
    Pyrhonen S, Salminen E, Ruutu M et al. (1999) Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 17: 2859–67PubMedGoogle Scholar
  10. 10.
    Collaborators MRCRC (1999) Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators. Lancet 353: 14–7CrossRefGoogle Scholar
  11. 11.
    Clark JI, Atkins MB, Urba WJ et al. (2003) Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. J Clin Oncol 21: 3133–40PubMedCrossRefGoogle Scholar
  12. 12.
    Yang JC, Sherry RM, Steinberg SM et al. (2003) Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 21: 3127–32PubMedCrossRefGoogle Scholar
  13. 13.
    Atzpodien J, Kirchner H, Jonas U et al. (2004) Interleukin-2-and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a prospectively randomized trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). J Clin Oncol 22: 1188–94PubMedCrossRefGoogle Scholar
  14. 14.
    Atzpodien J, Schmitt E, Gertenbach U et al. (2005) Adjuvant treatment with interleukin-2-and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). Br J Cancer 92: 843–6PubMedCrossRefGoogle Scholar
  15. 15.
    Jocham D, Richter A, Hoffmann L et al. (2004) Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet 363: 594–9PubMedCrossRefGoogle Scholar
  16. 16.
    Jacobsohn KM, Wood CG. Adjuvant therapy for renal cell carcinoma. Semin Oncol 33: 576–82Google Scholar
  17. 17.
    Lam JS, Leppert JT, Belldegrun AS et al. (2005) Adjuvant therapy of renal cell carcinoma: patient selection and therapeutic options. BJU Int 96: 483–8PubMedCrossRefGoogle Scholar
  18. 18.
    Garcia JA, Rini BI (2007) Recent progress in the management of advanced renal cell carcinoma. CA Cancer J Clin 57: 112–25PubMedCrossRefGoogle Scholar
  19. 19.
    Wood CG (2007) Multimodal approaches in the management of locally advanced and metastatic renal cell carcinoma: combining surgery and systemic therapies to improve patient outcome 10.1158/1078-0432.CCR-06-2109. Clin Cancer Res 13: 697s–702PubMedCrossRefGoogle Scholar
  20. 20.
    Jonasch E (2007) Presurgical therapy in metastatic renal cell carcinoma. Expert Rev Anticancer Ther 7: 73–8PubMedCrossRefGoogle Scholar
  21. 21.
    Flanigan RC, Salmon SE, Blumenstein BA et al. (2001) Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 345: 1655–9PubMedCrossRefGoogle Scholar
  22. 22.
    Mickisch GH, Garin A, van Poppel H et al. (2001) Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 358: 966–70PubMedCrossRefGoogle Scholar
  23. 23.
    Flanigan RC, Mickisch G, Sylvester R et al. (2004) Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 171: 1071–6PubMedCrossRefGoogle Scholar
  24. 24.
    Bex A, Horenblas S, Meinhardt W et al. (2002) The role of initial immunotherapy as selection for nephrectomy in patients with metastatic renal cell carcinoma and the primary tumor in situ. Eur Urol 42: 570–4PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag France, Paris 2008

Authors and Affiliations

  • Jean-Jacques Patard
    • 1
    • 2
  • Alain Ravaud
    • 3
  • Stéphane Oudard
    • 4
  1. 1.Service ďurologieCHU PontchaillouRennes cedex 9France
  2. 2.université de RennesRennesFrance
  3. 3.Département ďoncologie médicaleCHU Bordeaux, hôpital Saint-AndréBordeauxFrance
  4. 4.Département ďoncologie médicaleHôpital Européen Georges PompidouParisFrance

Personalised recommendations